ATE390412T1 - Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-3-azabicyclo(3,1,0)hexane-2- carboxamide,n-(3-amino-1-(cyclobutylmethyl)-2,3 dioxopropyl) )-3-((2s)-2-(((1,1- dimethylethyl)amino)carbonylamino)-3,3-dimethyl 1-oxobutyl)-6,6-dimethyl - Google Patents

Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-3-azabicyclo(3,1,0)hexane-2- carboxamide,n-(3-amino-1-(cyclobutylmethyl)-2,3 dioxopropyl) )-3-((2s)-2-(((1,1- dimethylethyl)amino)carbonylamino)-3,3-dimethyl 1-oxobutyl)-6,6-dimethyl

Info

Publication number
ATE390412T1
ATE390412T1 AT04755225T AT04755225T ATE390412T1 AT E390412 T1 ATE390412 T1 AT E390412T1 AT 04755225 T AT04755225 T AT 04755225T AT 04755225 T AT04755225 T AT 04755225T AT E390412 T1 ATE390412 T1 AT E390412T1
Authority
AT
Austria
Prior art keywords
dimethyl
amino
dioxopropyl
oxobutyl
cyclobutylmethyl
Prior art date
Application number
AT04755225T
Other languages
English (en)
Inventor
Anantha Sudhakar
Vilas Dahanukar
Ilia Zavialov
Cecilia Orr
Hoa Nguyen
Juergen Weber
Ingyu Jeon
Minzhang Chen
Michael Green
George Wong
Jeonghan Park
Tetsuo Iwama
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE390412T1 publication Critical patent/ATE390412T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04755225T 2003-06-17 2004-06-15 Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-3-azabicyclo(3,1,0)hexane-2- carboxamide,n-(3-amino-1-(cyclobutylmethyl)-2,3 dioxopropyl) )-3-((2s)-2-(((1,1- dimethylethyl)amino)carbonylamino)-3,3-dimethyl 1-oxobutyl)-6,6-dimethyl ATE390412T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47951703P 2003-06-17 2003-06-17

Publications (1)

Publication Number Publication Date
ATE390412T1 true ATE390412T1 (de) 2008-04-15

Family

ID=33539185

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04755225T ATE390412T1 (de) 2003-06-17 2004-06-15 Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-3-azabicyclo(3,1,0)hexane-2- carboxamide,n-(3-amino-1-(cyclobutylmethyl)-2,3 dioxopropyl) )-3-((2s)-2-(((1,1- dimethylethyl)amino)carbonylamino)-3,3-dimethyl 1-oxobutyl)-6,6-dimethyl

Country Status (12)

Country Link
US (1) US7326795B2 (de)
EP (1) EP1641754B1 (de)
JP (1) JP5219368B2 (de)
CN (2) CN102199111B (de)
AR (1) AR044694A1 (de)
AT (1) ATE390412T1 (de)
CA (1) CA2526629C (de)
DE (1) DE602004012746T2 (de)
ES (1) ES2299850T3 (de)
MX (1) MXPA05013753A (de)
WO (1) WO2004113294A1 (de)
ZA (1) ZA200509100B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR049635A1 (es) * 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
NZ563365A (en) * 2005-06-02 2011-02-25 Schering Corp Combination of HCV protease inhibitors with a surfactant
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
AU2006252519B2 (en) 2005-06-02 2012-08-30 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
JP5517454B2 (ja) * 2005-09-30 2014-06-11 スシネキス インク Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
AR056805A1 (es) * 2005-11-14 2007-10-24 Schering Corp Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
WO2007075790A1 (en) * 2005-12-22 2007-07-05 Schering Corporation Process for the preparation of 6, 6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds and enantiomeric salts thereof
JP5092289B2 (ja) * 2006-06-13 2012-12-05 三菱瓦斯化学株式会社 光学活性Ｎ−ｔｅｒｔ−ブチルカルバモイル−Ｌ−ｔｅｒｔ−ロイシンの製造方法
MX2009006477A (es) * 2006-12-15 2009-06-26 Schering Corp Purificacion de bisulfito de una alfa-ceto amida.
JP2010513492A (ja) 2006-12-19 2010-04-30 シェーリング コーポレイション ３−（アミノ）−３−（シクロブチルメチル）−２−（ヒドロキシ）−プロピオンアミド塩酸塩の調製
CA2672620A1 (en) * 2006-12-20 2008-07-03 Schering Corporation Process for preparing (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
EP2129658A2 (de) * 2006-12-20 2009-12-09 Schering Corporation Verfahren zur herstellung von 6,6-dimethyl-3-azabicyclo[3.1.0]hexanverbindungen unter anwendung eines bisulfit-zwischenprodukts
WO2009039361A2 (en) * 2007-09-20 2009-03-26 Virobay, Inc. Process for the preparation of (s)-2-(3-tert-butylureido)-3,3-dimethylbutanoic acid
WO2009063804A1 (ja) 2007-11-16 2009-05-22 Kaneka Corporation Ｎ－カルバモイル－ｔｅｒｔ－ロイシンの製造法
WO2009067225A2 (en) * 2007-11-20 2009-05-28 Concert Pharmaceuticals, Inc. Boceprevir derivatives for the treatment of hcv infections
EP2225203A1 (de) * 2007-11-28 2010-09-08 Schering Corporation Dehydrohalogenierungsverfahren zur herstellung von für die bereitstellung von 6,6-dimethyl-3-azabicyclo[3.1.0]hexanverbindungen nützlichen zwischenprodukten
JP5203468B2 (ja) * 2007-12-21 2013-06-05 メルク・シャープ・アンド・ドーム・コーポレーション ３−アミノ−３−シクロブチルメチル−２−ヒドロキシプロピオンアミドまたはその塩の合成のための方法
EP2303858A1 (de) * 2008-07-03 2011-04-06 Vertex Pharmceuticals Incorporated Zubereitung geschützter alpha-keto beta-aminoester und -amide
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
EP2704576A4 (de) * 2011-05-04 2014-12-10 Merck Sharp & Dohme Verfahren zur herstellung von hemmern des hepatitis-c-virus
CN104470914A (zh) * 2012-06-20 2015-03-25 桑多斯股份公司 替拉瑞韦和波普瑞韦或者其药学上可接受的盐或溶剂合物和中间产物包括经Mukaiyama羟醛加成制备的β-氨基酸的合成
WO2014061034A1 (en) * 2012-10-18 2014-04-24 Msn Laboratories Limited Process for preparation of boceprevir and intermediates thereof
US10238771B2 (en) 2012-11-08 2019-03-26 Edwards Lifesciences Corporation Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system
CN103936627B (zh) * 2013-01-18 2016-08-31 上海医药工业研究院 抗丙肝药物Boceprevir的中间体Ⅶ及其制备方法和应用
US20140256698A1 (en) * 2013-03-11 2014-09-11 Virobay, Inc. Cathepsin inhibitors
WO2015004685A2 (en) 2013-07-12 2015-01-15 Mylan Laboratories Ltd An improved process for the purification of boceprevir
WO2015054662A1 (en) 2013-10-10 2015-04-16 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
CN104744291B (zh) * 2015-02-13 2017-01-11 宁波九胜创新医药科技有限公司 N-苄基-4-环丁基-2-羟基-3-硝基丁酰胺及其用途
WO2018035249A1 (en) * 2016-08-16 2018-02-22 Imago Biosciences, Inc. Compositions and methods for producing stereoisomerically pure aminocyclopropanes
CN115784968A (zh) * 2022-12-20 2023-03-14 黄冈鲁班药业股份有限公司 Paxlovid和波普瑞韦中间体的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT672041E (pt) * 1993-10-01 2002-04-29 Novartis Ag Derivados da piridina farmacologicamente activos e processos para a sua preparacao
DK1385870T3 (da) * 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus

Also Published As

Publication number Publication date
WO2004113294A1 (en) 2004-12-29
CN102199111B (zh) 2012-07-04
EP1641754A1 (de) 2006-04-05
JP2006528133A (ja) 2006-12-14
HK1084387A1 (en) 2006-07-28
AR044694A1 (es) 2005-09-21
DE602004012746D1 (de) 2008-05-08
US20050059800A1 (en) 2005-03-17
EP1641754B1 (de) 2008-03-26
MXPA05013753A (es) 2006-03-08
ES2299850T3 (es) 2008-06-01
US7326795B2 (en) 2008-02-05
CA2526629A1 (en) 2004-12-29
CN1805932A (zh) 2006-07-19
CN1805932B (zh) 2011-05-18
CA2526629C (en) 2012-10-02
JP5219368B2 (ja) 2013-06-26
CN102199111A (zh) 2011-09-28
ZA200509100B (en) 2011-06-29
DE602004012746T2 (de) 2009-04-09

Similar Documents

Publication Publication Date Title
ATE390412T1 (de) Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-3-azabicyclo(3,1,0)hexane-2- carboxamide,n-(3-amino-1-(cyclobutylmethyl)-2,3 dioxopropyl) )-3-((2s)-2-(((1,1- dimethylethyl)amino)carbonylamino)-3,3-dimethyl 1-oxobutyl)-6,6-dimethyl
DE69841653D1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
EP1680109A4 (de) Amid-derivate als ionenkanal-liganden und pharmazeutische zusammensetzungen und anwendungsverfahren
DE60323994D1 (de) Verfahren zur herstellung von 2-chlor-1,1,1,2,3,3,3-heptafluorpropan, hexafluorpropen und 1,1,1,2,3,3,3-heptafluorpropan
DE60328502D1 (de) Verfahren zur herstellung von 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazolen aus cyclohexanen und cycylohexanonen als zwischenprodukte
ZA200904330B (en) Process for preparing (1R, 2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2-3-dioxopropyl]-3-3[(2S)-2[[[1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
ATE399536T1 (de) Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
ATA9042002A (de) Zusammensetzungen zur herstellung von aminoplasterzeugnissen
ZA200804110B (en) An oxidation process for the preparation of N-[3-amino-1-(cyclobutylmethyl)-2,3- dioxopropyl]-3-{N-[(tert-buty-lamino)carbonyl]-3-methyl-L-valyl}-6,6-dimethyl-3-azabicy-clo[3.1.0]hexane-2-carboxamide and related compounds
ATE315043T1 (de) Verfahren für die synthese von perindopril und seiner pharmazeutischen annehmbaren salzen
ATE354586T1 (de) Verfahren für die synthese von perindopril und seiner pharmazeutischen annehmbaren salzen
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
ATE294814T1 (de) Verfahren für die synthese von perindopril und seiner pharmazeutischen annehmbaren salzen
ATE306496T1 (de) Verfahren für die synthese von perindopril und seiner pharmazeutischen annehmbaren salzen
DE50205026D1 (de) Verfahren zur herstellung von n-substituierten 2,6-dialkylmorpholinen
MA27110A1 (fr) Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2004206257A8 (en) Human SAA3 nucleic acid molecule, protein, and methods of use for same
EP1498145A4 (de) LOCKSTOFF ZUR BEHANDLUNG UND/ODER PRÄVENTION VON Th2 CYTOKIN-ASSOZIIERTEN ALLERGISCHEN ERKRANKUNGEN, GATA3 MUTANT-PROTEIN UND DIESES ENTHALTENDE MEDIZINISCHE ZUSAMMENSETZUNGEN
EP1636383A4 (de) Das tctp-gen aus säugern oder dessen proteinprodukt umfassende zusammensetzung zum screening eines bluthochdruckmittels und verfahren zum screening auf ein bluthochdruckmittel unter verwendung der zusammensetzung
DE60303104D1 (de) Verfahren zur Herstellung von N-((S)-1-(Etoxycarbonyl)butyl)-(S)-alanin und Verwendung in der Synthese von Perindopril
ATE338058T1 (de) Verfahren für die synthese von perindopril und seiner pharmazeutischen annehmbaren salzen
ATE337332T1 (de) Verfahren für die synthese von perindopril und seiner pharmazeutischen annehmbaren salzen
WO2006000464A3 (de) Verfahren zum auffinden schmerzrelevanter substanzen unter verwendung schmerzrelevanter proteine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties